IgG anti-hGPA mAbs rapidly cleared hGPA-Tg-mRBC in vivo
| mAb . | IgG subclass . | No. of mice . | Percent 4-h RBC survival, mean ± 1 SD . |
|---|---|---|---|
| 10F7 | IgG1 | 5 | 59.9 ± 3.4 |
| NaM10-6G4 | IgG2a | 4 | 29.6 ± 9.2 |
| NaM10-2H12 | IgG3 | 10 | 17.0 ± 7.2 |
| mAb . | IgG subclass . | No. of mice . | Percent 4-h RBC survival, mean ± 1 SD . |
|---|---|---|---|
| 10F7 | IgG1 | 5 | 59.9 ± 3.4 |
| NaM10-6G4 | IgG2a | 4 | 29.6 ± 9.2 |
| NaM10-2H12 | IgG3 | 10 | 17.0 ± 7.2 |
Wild-type FVB/NJ recipient mice that had been passively immunized intraperitoneally with mAb 10F7 (500 μg), NaM10-6G4 (50 μg), or NaM10-2H12 (50 μg) were then transfused 16 hours later with 51Cr-labeled hGPA-Tg-mRBCs and the 4-hour RBC survivals were determined as described in “Materials and methods.”